Atrial Fibrillation Management with Intermediate Risk

Risk Assessment and Anticoagulation

The American College of Cardiology recommends that patients with atrial fibrillation and a CHA₂DS₂-VASc score of 1 should be offered oral anticoagulation to prevent stroke, as this intermediate-risk group has an annual stroke rate of approximately 1.4-2.3% without treatment, which exceeds the threshold justifying anticoagulation 1, 2
A CHA₂DS₂-VASc score of 1 represents an intermediate stroke risk, with adjusted annual event rates ranging from 1.4% to 2.3% depending on which specific risk factor is present 2
The threshold for justifying oral anticoagulation is generally accepted as 1% annual stroke risk, which all CHA₂DS₂-VASc 1 subgroups exceed 2
Current guidelines recommend that stroke prevention should be offered to patients with 1 or more non-sex CHA₂DS₂-VASc stroke risk factors 1

If the patient is female with no other risk factors (score = 1 from sex alone), do NOT initiate anticoagulation, as this represents truly low risk 1
If the patient is male with one risk factor OR female with one additional risk factor beyond sex, proceed with anticoagulation consideration 1, 3
Calculate HAS-BLED score to identify modifiable bleeding risk factors (hypertension, abnormal renal/liver function, stroke, bleeding history, labile INR, elderly, drugs/alcohol) 1, 4
A HAS-BLED score ≥3 requires more frequent monitoring but is NOT a contraindication to anticoagulation 1, 4

Direct Oral Anticoagulants (DOACs) are preferred over warfarin for patients with nonvalvular AF 3, 6
Options include apixaban, dabigatran, rivaroxaban, and edoxaban 3, 6
Warfarin (target INR 2.0-3.0) is recommended if DOACs are contraindicated, not tolerated, or in specific situations such as moderate or severe mitral stenosis, mechanical prosthetic heart valves, or severe renal impairment 3, 4, 5, 6

The recommendation applies regardless of AF pattern (paroxysmal, persistent, or permanent) 3
Antiplatelet therapy (aspirin, clopidogrel) is NOT recommended as an alternative to anticoagulation for stroke prevention in AF 5
Assess renal function before initiating DOACs and reassess at least annually 6

Do not withhold anticoagulation solely based on elevated HAS-BLED score—instead, address modifiable bleeding risk factors 1, 4
Do not count female sex alone as justifying anticoagulation (this represents CHA₂DS₂-VASc 0 for women) 1
Do not use aspirin as stroke prevention in AF patients with CHA₂DS₂-VASc ≥1, as it is ineffective and still carries bleeding risk 5
Do not prescribe DOACs for mechanical heart valves or moderate-to-severe mitral stenosis 3, 5, 4